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method of intervention, complications, and recurrence.
RESULTS Of the 112 patients who went to the lab, we analyzed data
encompassing 216 veins with 39 veins not intervened upon secondary
to complete occlusion or lack of substantial PV-LA pressure gradient.
After an initial 94% procedural success rate, there were 76 PVS re-
currences (44%) over a median follow up time of 4.6 years. We found
those who experienced PVS recurrence had signiﬁcantly higher post-
procedure PV/LA gradients (3.84.9 mmHg vs 1.71.8 mmHg,
p¼0.001) compared to those who avoided recurrence. Patients who
underwent initial stenting compared to balloon dilatation had a 44%
reduction in recurrence compared to those who underwent balloon
dilatation only (RR¼0.56, 95% CI 0.41 to 0.75, p<0.0001, Figure 1). We
also note signiﬁcantly higher balloon atmosphere inﬂations among
patients who did not recur (9.14.0 atm vs 7.32.3 atm, p¼0.007) with
no difference in pre-procedural lesion characteristics or stent/balloon
size.
CONCLUSIONS These results demonstrate PVS recurrence is com-
mon, and is more likely to occur over a lengthy follow up in those
who initially underwent balloon dilatation compared to stenting.
Furthermore, difﬁcult lesions where higher balloon insufﬂation
cannot be achieved resulting in higher post-procedure PV/LA gradi-
ents are more likely to result in recurrence. Thus, PVS should be
initially treated with stenting to avoid further sequelae of PVI such as
recurrent PVS.
CATEGORIES CORONARY: Complex and Higher Risk Procedures for
Indicated Patients (CHIP)
KEYWORDS Stent, Transseptal puncture, Venous stenting
TCT-28
Treat and Repair Strategies for Adult Patients with Atrial Septal Defect and
Severe Pulmonary Atrial Hypertension
Teiji Akagi,1 Yasufumi Kijima,2 Yoichi Takaya,1 Koji Nakagawa,1
Shunji Sano,1 Hiroshi Ito3
1Okayama University Hospital, Okayama, Japan; 2David Geffen School
of Medicine at UCLA, Los Angeles, CA; 3Okayama University, Okayama,
Japan
BACKGROUND Optimal therapeutic strategies for patients with
atrial septal defect (ASD) complicated with severe pulmonary arte-
rial hypertension (PAH) is controversial. Combination of recent
advanced PAH speciﬁc medication and transcatheter ASD closure
may contribute the improvement of therapeutic outcome in these
difﬁcult patients population. Our purpose was to evaluate the efﬁ-
cacy of PAH-speciﬁc medications combined with transcatheter
closure.
METHODS Between January 2006 and December 2013, 780 patients
with ASD were performed transcatheter closure, and 48 of 780 pa-
tients (6.2%) complicated with PAH (mean pulmonary artery
pressure  25 mm Hg). Following patients were excluded from thisstudy because of pulmonary hypertension related to lung diseases
(n¼8), left ventricular systolic dysfunction (n¼1) and pulmonary em-
bolism (n¼1). Among 38 patients with PAH associated with ASD, 3
patients excluded because the defects was too large for device
deployment. A total of 35 patients underwent successful procedures
and were included in this study. Among of these, 8 patients with se-
vere PAH required of PAH-speciﬁc medication (PAH speciﬁc group)
and compared to 40 patients who did not required of PAH-speciﬁc
medication (non PAH-speciﬁc group) were studied. PAH-speciﬁc
medications included an endothelin receptor antagonist (bosentan;
n ¼ 4), a phosphodiesterase type-5 inhibitor (sildenaﬁl; n ¼ 4), an oral
prostanoid (beraprost; n ¼ 1), and an intravenous prostanoid (epo-
prostenol; n ¼ 2).
RESULTS After the induction of PAH speciﬁc medication (mean 6.6
months), transcatheter ASD closure was successfully performed in all
without hemodynamic intolerances. Mean device size was 26  7 mm
and the mean ﬂuoroscopic time was 15  8 min. Multiple devices were
required in 2 patients. No hemodynamic compromise occurred in any
of the patients during or after the procedure. Improvement of systolic
PAP was signiﬁcantly greater in PAH-speciﬁc group compared to non
PAH-speciﬁc group (median, 49; range, 26 to 105 mm Hg vs. median,
14; range 4 to 77 mm Hg, respectively; p ¼ 0.0014). Among 29 patients
with symptomatic heart failure, improved heart failure symptoms was
observed in 21 (72%) patients with no exacerbation of heart failure.
Compared with the initial evaluation, BNP levels signiﬁcantly
improved at follow-up at follow-up period (p ¼ 0.0017). During the
mean observational period of 45  25 months, one patient required
hospital admission due to the progression of sick sinus syndrome. No
other adverse events including hospitalization of exacerbation of PAH
were observed.
CONCLUSIONS Even in patients with severe PAH, who initially did
not fulﬁll the indication of transcatheter ASD closure, the recent PAH
speciﬁc medication can contribute the signiﬁcant improvement of
hemodynamic condition. This treat and repair strategies may expand
of therapeutic indication for transcatheter ASD closure in patients
with severe PAH.
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BACKGROUND Transcatheter closure of large post-tricuspid shunts
in patients with severe pulmonary arterial hypertension (PAH) re-
mains a challenging clinical problem. In neonates and infants it is
most often reversible, but in older patients the resolution of PAH
is variable depending on the reversibility of pulmonary vascular
resistance. The current study was done to assess the safety and ef-
ﬁcacy of percutaneous device closure of large post tricuspid
shunts in pediatric patients with severe PAH at short and mid term
follow up.
METHODS A total of 42 pediatric patients underwent transcatheter
closure of large post tricuspid shunts with severe PAH. All subjects
underwent clinical examination, electrocardiography, chest x-rays
and echocardiography before discharge and at 1, 6 and 12 months after
the procedure and yearly thereafter for 5 years.
RESULTS Type of defect was ventricular septal defect in 8 patients
(19%), patent ductus arteriosus in 27 patients (64%), aorto-pulmonary
window in 5 patients (12%) and coronary cameral ﬁstula in two pa-
tients (5%). Cardi-O-Fix VSD occluder was the most commonly used
device (45%), Cardi-O-Fix PDA occluder (21%) and Amplatzer duct
occlude in 17% patients. Pre-procedural pulmonary artery systolic
pressure decreased signiﬁcantly from mean 81.12 mmHg to mean
43.17 mmHg post procedure over a mean follow-up of 18.5 months. No
residual shunt was found in 38 (90.47%) patients. Only two major
complications viz; severe aortic obstruction and symptomatic com-
plete heart block were noticed.
